Lily Y. Moy

Lily Y. Moy

Auto-generated profile, based on publicly available information

Lily Y. Moy

Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, Massachusetts 02115, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2006 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
JCJonathan C. Cruz
Jonathan C. Cruz
DKDo Hoon Kim
Do Hoon Kim
LMLily Y. Moy
Lily Y. Moy
MDMatthew M. Dobbin
Matthew M. Dobbin
XSXiaoyan Sun
Xiaoyan Sun
LTLi-Huei Tsai
Li-Huei Tsai
Aberrant processing of the amyloid precursor protein (APP) and the subsequent accumulation of amyloid β (Aβ) peptide has been widely established as a central event in Alzheimer's disease (AD) pathogenesis. The sequential cleavage steps required for the generation of Aβ are well outlined; however, there is a relative dearth of knowledge pertaining to signaling pathways and molecular mechanisms that can modulate this process. Here, we demonstrate a novel role for p25/cyclin-dependent kinase 5 (Cdk5) in regulating APP processing, Aβ peptide generation, and intraneuronal Aβ accumulation in inducible p25 transgenic and compound PD–APP transgenic mouse models that demonstrate deregulated Cdk5 activity and a neurodegenerative phenotype. Induction of p25 resulted in enhanced forebrain Aβ levels before any evidence of neuropathology in these mice. Intracellular Aβ accumulated in perinuclear regions and distended axons within the forebrains of these mice. Evidence for modulations in axonal transport or β-site APP cleaving enzyme 1 protein levels and activity are presented as mechanisms that may account for the Aβ accumulation caused by p25/Cdk5 deregulation. Collectively, these findings delineate a novel pathological mechanism involving aberrant APP processing by p25/Cdk5 and have important implications in AD pathogenesis.

9 February 2024 in Cancer Research
Verified
Journal Article
Open access
PDF file
HXHandan Xiang
Handan Xiang
YPYidan Pan
Yidan Pan
MSMarc Alexander Sze
Marc Alexander Sze
MWMarta Wlodarska
Marta Wlodarska
LLLing Li
Ling Li
ALAndrey Loboda
Andrey Loboda
Cancer immunotherapy has revolutionized the treatment of lung adenocarcinoma (LUAD); however, a significant proportion of patients do not respond. Recent transcriptomic studies to understand determinants of immunotherapy response have pinpointed stromal-mediated resistance mechanisms. To gain a better understanding of stromal biology at the cellular and molecular level in LUAD, we performed single-cell RNA sequencing of 256,379 cells, including 13,857 mesenchymal cells, from 9 treatment-naïve patients. Among the mesenchymal cell subsets, FAP+PDPN+ cancer-associated fibroblasts (CAF) and ACTA2+MCAM+ pericytes were enriched in tumors and differentiated from lung-resident fibroblasts. Imaging mass cytometry revealed that both subsets were topographically adjacent to the perivascular niche and had close spatial interactions with endothelial cells (EC). Modeling of ligand and receptor interactomes between mesenchymal and ECs identified that NOTCH signaling drives these cell-to-cell interactions in tumors, with pericytes and CAFs as the signal receivers and arterial and PLVAPhigh immature neovascular ECs as the signal senders. Either pharmacologically blocking NOTCH signaling or genetically depleting NOTCH3 levels in mesenchymal cells significantly reduced collagen production and suppressed cell invasion. Bulk RNA sequencing data demonstrated that NOTCH3 expression correlated with poor survival in stroma-rich patients and that a T cell–inflamed gene signature only predicted survival in patients with low NOTCH3. Collectively, this study provides valuable insights into the role of NOTCH3 in regulating tumor stroma biology, warranting further studies to elucidate the clinical implications of targeting NOTCH3 signaling. Significance: NOTCH3 signaling activates tumor-associated mesenchymal cells, increases collagen production, and augments cell invasion in lung adenocarcinoma, suggesting its critical role in remodeling tumor stroma.

7 December 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DCDavid A. Candito
David A. Candito
VSVladimir Simov
Vladimir Simov
AGAnmol Gulati
Anmol Gulati
SKSolomon Kattar
Solomon Kattar
RCRyan W. Chau
Ryan W. Chau
JEJ. Michael Ellis
J. Michael Ellis

20 October 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SKSolomon D. Kattar
Solomon D. Kattar
AGAnmol Gulati
Anmol Gulati
KMKaila A. Margrey
Kaila A. Margrey
MKMitchell H. Keylor
Mitchell H. Keylor
MAMichael Ardolino
Michael Ardolino
PFPeter H. Fuller
Peter H. Fuller

4 September 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
KLKaitlyn M. Logan
Kaitlyn M. Logan
WKWill Kaplan
Will Kaplan
VSVladimir Simov
Vladimir Simov
HZHua Zhou
Hua Zhou
DLDerun Li
Derun Li
PFPeter H. Fuller
Peter H. Fuller

29 April 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XZXiao Mei Zheng
Xiao Mei Zheng
DCDavid A. Candito
David A. Candito
JJJames Jewell
James Jewell
MCMatthew Childers
Matthew Childers
SKShuhei Kawamura
Shuhei Kawamura
SSStuart Shumway
Stuart Shumway